Evidence map›Paper›PMID 42026088›Full record

ArticleNPJ Regenerative medicine2026

The SHEDs-derived apoptotic bodies for inflammatory regulation in spinal cord repair.

Lihua Luo, Na Dong, Junpeng Xu, Chen Zhang, Sa Bao, Haichao Xu, Xiping Wang, Peng Dai, Caiyan Li, Qiao Zhang and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lihua Luo *School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China.
Na Dong *The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Junpeng Xu *The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Chen ZhangSchool and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China.
Sa BaoSchool and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China.
Haichao XuSchool and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China.
Xiping WangSchool and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China.
Peng DaiOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), National Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Caiyan LiOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), National Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Qiao ZhangThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yibo YingThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Dawei JiangThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Shengcun LiOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), National Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Ping WuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Liqing MeiSchool and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China.
Xiaokun LiThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. xiaokunli@wmu.edu.cn.
Junjie DengJoint Centre of Translational Medicine, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, China. j.deng@ucas.ac.cn.
Yihuai PanSchool and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China. yihuaipan@wmu.edu.cn.
Zhouguang WangThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. wangzhouguang@wmu.edu.cn.

Funding

Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang 2023R01002Ningbo Natural Science Foundation 2024J359Postdoctoral Fellowship Program of CPSF GZC20241251Zhejiang Provincal Postdoctoral Science Foundation ZJ2024168
6 · The paper itself

Abstract

Neuroinflammation is a key therapeutic target for spinal cord injury (SCI). Apoptotic bodies (ABs) derived from mesenchymal stem cells may modulate early inflammation, promoting SCI repair. Stem cells from human exfoliated deciduous teeth (SHEDs), with neural crest origins, are promising for neurological therapies, but their ABs' role in SCI remains unclear. In this study, as exploratory research, we aimed to investigate the preliminary effects and mechanisms of SHEDs-derived ABs on the treatment of SCI. Herein, SHEDs-derived ABs enhanced functional recovery in SCI mice, improving BMS scores, joint movement, and bioelectrical conduction. Histologically, ABs boosted axonal growth and neuronal regeneration. Moreover, SHEDs-derived ABs significantly suppressed M1 polarization while enhancing M2 polarization in both in vitro and in vivo models. GO/KEGG analyses revealed AB enrichment in immune-related pathways. Mechanistically, the ANXA1/FPR2 axis was critical for ABs-induced microglia/macrophage polarization, with M1 regulation mediated by the NF-κB pathway and M2 modulation driven by the AKT/mTOR pathway. Thus, SHEDs-derived ABs may serve as a clinically translatable strategy for treating SCI by mediating immunomodulation via the ANXA1/FPR2 axis.

Identifiers

PMID42026088
PMCPMC13316036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.